Treatment of ventricular premature contractions (premature ventricular contractions) should be risk-stratified with different therapeutic measures. 1. Ventricular premature contractions without organic heart disease, even if they are frequent on Holter’s examination or a few polymorphic, paired, or cascading ventricular premature contractions, generally have a good prognosis and do not support conventional antiarrhythmic drug therapy from the perspective of the risk-benefit ratio. Patients should be removed from predisposing factors, and sedatives or low-dose β-blockers (e.g., metoprolol, bisoprolol) can be used for those with mental stress and anxiety, with the therapeutic endpoint of symptom relief rather than a significant reduction in the number of ventricular premature contractions. 2. Ventricular premature contractions in patients with organic heart disease, especially complex (polymorphic, paired, cascade) ventricular premature contractions with cardiac insufficiency, have a poor prognosis. Risk stratification should be performed according to medical history, complexity of ventricular asystole, left ventricular ejection fraction, etc. The higher the risk, the more intensive the treatment should be. The primary disease should be treated first and the contributing factors should be controlled, based on which β-blockers are used as starting treatment. class III antiarrhythmics (amiodarone) can be used in patients with complex ventricular prophase contractions. In patients with non-myocardial infarction with organic heart disease, propafenone, mexiletine, and morethizine are effective and relatively safe. 3. They can also be treated with herbal tonics or Chinese herbal medicines.